Skip to content
Homepage
Author:
Ambrosia Biosciences
Posted Date:
June 5, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
Ambrosia Biosciences
June 5, 2026
Ambrosia Biosciences Announces Late-Breaking Poster Presentation at the American Diabetes Association’s (ADA) 86th Scientific Session
Ambrosia Biosciences
April 21, 2026
Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline
Ambrosia Biosciences
March 31, 2026
